ReviewMedical oncology (Northwood, London, England)2025
Pterostilbene as a promising natural anticancer agent in gynecological cancers.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gynecological cancer, encompassing cancers such as endometrial and cervical cancer, is a growing concern worldwide, with a rising incidence and significant impact on women's health. Pterostilbene (PT), a natural compound, has shown promising therapeutic potential in gynecological cancer treatment. This review aims to summarize the current state of knowledge on PT's effects in gynecological cancer, focusing on its molecular mechanisms, preclinical studies, and clinical trials. A comprehensive literature search was conducted using databases, such as Google Scholar, PubMed, Wiley Online Library, Scopus, and Web of Science, covering studies published over the last 10 years (2015-2025). The search focused on PT's therapeutic potential in gynecological cancer, including its synergistic action with other therapies or natural compounds. The review highlights PT's ability to modulate key signaling pathways, induce apoptosis, and inhibit cell cycle progression in endometrial carcinoma cells and cervical cancer cells. Preclinical studies demonstrate PT's efficacy in reducing tumor size and enhancing anti-tumor activity when pterostilbene (PT) is combined with megestrol acetate (MA). Clinical trials suggest that PT combined with MA may be a promising therapeutic strategy for endometrial cancer treatment. Overall, this review provides a comprehensive overview of PT's therapeutic potential in gynecological cancer and highlights its promise as a potential treatment option. Further research is needed to fully establish PT's efficacy and safety in gynecological cancer patients. Notably, our literature search did not yield sufficient studies related to vulvar or vaginal cancers, highlighting a significant gap in the current research landscape.
Indexed as
Identifiers
40924333What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.